. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
Cost of sales and service Cost was 283.2 MB, an increase by 47.3 MB or 20% y-o-y is in alignment with the growth sale trend. The Company can control the cost of materials and labor costs in effectively
; caption-side: bottom; } th { // Matches default `` alignment by inheriting from the ``, or the // closest parent with a set `text-align`. text-align: inherit; } // // Forms // label { // Allow
enhance suitability for the characteristics of digital assets and types of associated risks Businesses and in alignment with the specific characteristics and risks associated with different types of digital
characteristics of digital assets and types of associated risks Businesses and in alignment with the specific characteristics and risks associated with different types of digital assets * while adhering to